J. David Enloe, Jr., CEO of Ajinomoto Althea (“Althea”) was awarded Most Admired CEO in 2017 by the San Diego Business Journal. This award recognized David for leading Althea through a phase of significant growth while fostering several technical innovation and organizational development initiatives. Under Enloe’s leadership, Althea achieved its highest revenue in its 18 year history in 2016 and has grown its revenues by 25 percent year-over-year for the last 3 years, when he came to San Diego to take over Althea soon after its acquisition by Ajinomoto, a large Japanese firm.
This award acknowledges David for guiding Althea to achieve a four-fold increase in the number of manufactured commercially approved drug products and for the expansion from 1 to 8 countries that have authorized commercial use of Althea’s products. In addition to this strong growth, David has launched several new initiatives to foster further growth for Althea over the upcoming years. He drove Althea’s entry into the rapidly growing oncology field of antibody drug conjugate (ADC) manufacturing which will enable the company to partner with more clients globally.
Enloe was recognized for spearheading negotiations of the first multimillion dollar license of Althea’s proprietary Crystalomics formulation technology, monetizing many of the Crystalomics patents, and launching a new company technology and service offering. Althea now has Crystalomics contracts with six of the top ten BioPharma companies in the world.
The Most Admired CEO award further noted that David was recently appointed a Corporate Executive Officer of Ajinomoto Co in addition to serving as President and CEO of Althea. He now acts as one of only two Americans who will participate in establishing strategic objectives for the overall global conglomerate.
Under Enloe’s leadership, Althea received a number of prestigious honors including five categories in this year’s Contract Manufacturing Organization Leadership Awards. He has represented Althea as a speaker at multiple industry conferences on the East Coast and West Coast, contributing to the growth and development of the company’s client base.
Finally, David was recognized for leading Althea’s Cultural Value Initiative which has increased employee satisfaction and engagement, and attracted top talent to Althea from across the world. This award of Most Admired CEO is a testament to Althea’s commitment to excellence in all areas of the company and is driven by Enloe’s leadership and vision.
About Ajinomoto Althea, Inc.
Ajinomoto Althea, Inc. is a fully integrated, contract development and manufacturing organization located in San Diego, CA providing clinical and commercial product development services. Ajinomoto Althea, Inc. offers cGMP drug product filling in both vials and syringes, and production of microbial-derived recombinant proteins and plasmid DNA. In conjunction with these manufacturing operations, Ajinomoto Althea, Inc. offers comprehensive development services including: upstream and downstream process development, analytical development, lyophilization cycle, complex formulation, product release and ICH-compliant stability testing. Ajinomoto Althea Inc.'s formulation technology platform includes Crystalomics, a proprietary technology that offers a formulation solution for large molecule products that must be delivered at high concentrations or as sustained release formulations. Ajinomoto Althea also has an innovative and proven recombinant protein expression technology called Corynex technology. For more information, visit www.altheaCMO.com.
SOURCE: Ajinomoto Althea, Inc.